The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Effects of Testosterone Treatment in Older Men
Open accessAbstract
BACKGROUND: Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. METHODS: We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials--the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. RESULTS: Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P=0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. CONCLUSIONS: In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“there is accumulating evidence against a link between testosterone therapy and prostate cancer development.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [24]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ‘Testosterone Trials’, treatment with testosterone improved participants’ results in the 6 min walk test compared with placebo (20.5% versus 12.6%; P = 0.003)53.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Randomized controlled trials have shown that there is not a significant increase in the rate of a prostate cancer diagnosis in older, testosterone deficient men who were treated with testosterone compared to placebo.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [24]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In trials, patients with low testosterone have demonstrated statistically significant improvements in erectile function, 24 sex drive, 24 anemia, 25 bone mineral density, 26 lean body mass, 27 and depressive symptoms. 24”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [24]
In the citing paper
“Testosterone supplementation is also shown to benefit other aspects of health, including sexual function, physical function, vitality, quality of life and improved mood [109, 111].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [111]
In the citing paper
“Of note, potential improvements in muscle (and lean) mass may not directly result in improved muscle function214,215.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [214]
In the citing paper
“In the large T Trials, sexual function improved modestly with testosterone treatment,”
From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [37]
In the citing paper
“suggesting that even older men with a relatively high comorbid burden (37% had diabetes and 15% a previous myocardial infarction) can respond to testosterone.37”
From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [37]
In the citing paper
“In the Testosterone Trials of stringently selected symptomatic men with a baseline testosterone averaging < 9.5 nmol/L (275 ng/dL) for no apparent reason other than age, testosterone treatment had a modest benefit in sexual function, and some benefit with respect to mood and depressive symptoms (15).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“In an intensive lifestyle randomized controlled trial (RCT) of relatively healthy obese middle-aged men, 15% weight loss increased the mean International Index of Erectile Function (IIEF) score by 3.10, which is clinically meaningful (23) and similar to the increase of 2.64 reported in the Testosterone Trials, although those men were older (15).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“Although head-to-head studies are lacking, the efficacy reported for PDE5 inhibitors is greater than that reported for lifestyle intervention and testosterone treatment (15, 25).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“In RCTs of middle-aged and older men, where contraindications have been rigorously excluded and treatment was carefully monitored, short-term testosterone treatment has been associated with a low risk of adverse events (15).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“Although the trial was too small to reliably assess testosterone treatment-associated risks (15)”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“it does provide some assurance about the potential relative short-term safety of testosterone treatment in men without the previously mentioned contraindications.”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“These guideline recommendations are consistent with the exclusion criteria specified in the Testosterone Trials (15).”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
In the citing paper
“In the 12-month Testosterone Trials, the rates of adverse events were similar in the testosterone- and placebo-treated men.”
From A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management (2017) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling
Terza, J. V., Basu, A., & Rathouz, P. J. (2008) · Journal of Health Economics · doi:10.1016/j.jhealeco.2007.09.009 · Cited by 1,728
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationThe International Index of Erectile Function (IIEF): a state-of-the-science review
Rosen, R., Cappelleri, J. C., & Gendrano, N. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900857 · Cited by 1,050
Self-citationRedelmeier, D. A., Bayoumi, A. M., Goldstein, R. S., & Guyatt, G. H. (1997) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.155.4.9105067 · Cited by 1,029
Research works printed but not linked: 1
- Ware J, Kosinski M. SF-36 Physical and Mental Health Summary Scales: a manual for users of Version 1, Second Edition. Lincoln, RI: Quality Metric, 2005.
Cited by
Sorted by citations
Items 401–500 of 891
Dimitropoulos, K., Verze, P., den Broeck, T. V., Salonia, A., Yuan, C. Y., Konstantinos Hatzimouratidis, A., & Dohle, G. R. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0131-1 · Cited by 11
Święcicka, A., Piasecki, M., Stashuk, D. W., Jones, D. A., Wu, F. C. W., McPhee, J. S., & Rutter, M. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa100 · Cited by 12
Swerdloff, R. S., & Wang, C. (2020) · Andrology · doi:10.1111/andr.12901 · Cited by 11
Self-citationHypogonadism and cancer survivorship
Faw, C. A., & Brannigan, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000583 · Cited by 11
Zhong, S.-R., Yang, H.-H., Liao, C.-H., Yang, D., Tu, S.-K., Hung, C.-L., & Liao, C. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s282832 · Cited by 11
Late-Onset Hypogonadism as Primary Testicular Failure
Swee, D. S., & Gan, E. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00372 · Cited by 11
Morley, J. E., & Bauer, J. M. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000531 · Cited by 11
Anawalt, B. D., O’Connor, K., & Grossmann, M. (2026) · JAMA · doi:10.1001/jama.2026.8526 · Cited by 11
Yang, H. J., Kim, K. H., Kim, D. S., Lee, C. H., Jeon, Y. S., Shim, S. R., & Kim, J. H. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220171 · Cited by 10
Kosidou, K., Karlsson, H., Arver, S., Bhasin, S., Dalman, C., & Gardner, R. M. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.02.1014 · Cited by 12
Self-citationRasmussen, R. S., Midttun, M., Zerahn, B., Pedersen, M., Rashid, A., Østergren, P. B., Paulin, T. K., Pødenphanth, T. W., Karlsson, L. K., Rosendahl, E., et al. (2024) · The Aging Male · doi:10.1080/13685538.2024.2403519 · Cited by 13
Testosterone Therapy in Older Men: Present and Future Considerations
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01209-1 · Cited by 10
Braga, M. A. P., Rivera, A., Marinheiro, G., Felix, N. S., Carvalho, P. E. P., Gewehr, D. M., Teixeira, L., Clemente, M. R. C., Reis, P. C. A., de Amorim, L. G. C. R., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00737-w · Cited by 10
Chasland, L. C., Knuiman, M. W., Divitini, M., Chan, Y. X., Handelsman, D. J., Naylor, L. H., GREEN, D. J., & Yeap, B. B. (2017) · Clinical Endocrinology · doi:10.1111/cen.13407 · Cited by 11
Trials of testosterone replacement reporting cardiovascular adverse events
Basaria, S. S., & Gagliano‐Jucá, T. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_28_17 · Cited by 10
Self-citationRisk factors for hypogonadism in young men with erectile dysfunction
Huang, I.-S., Mazur, D. J., Kahn, B. E., Keeter, M. K., Desai, A. S., Lewis, K., Tatem, A. J., Hehemann, M. C., Brannigan, R. E., & Bennett, N. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000099 · Cited by 10
Valderrábano, R. J., Pencina, K. M., Storer, T. W., Reid, K. F., Kibel, A. S., Burnett, A. L. “., Huang, G. T.-W., Dorff, T. B., Privat, F., Ghattas, C., et al. (2022) · Andrology · doi:10.1111/andr.13299 · Cited by 10
Self-citationCao, X., Yang, B., & Zhou, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1166341 · Cited by 10
Testosterone and type 2 diabetes prevention: translational lessons from the T4DM study
Wittert, G., Grossmann, M., Yeap, B. B., & Handelsman, D. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0223 · Cited by 10
Chrysant, S. G., & Chrysant, G. S. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1445405 · Cited by 11
Peyronie’s disease and testosterone deficiency: Is there a link?
Aditya, I., Grober, E. D., & Krakowsky, Y. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02723-9 · Cited by 10
Stephens‐Shields, A. J., Wang, C., Preston, P. E., Snyder, P. J., & Swerdloff, R. S. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.04.003 · Cited by 10
Self-citationSíndrome de déficit de testosterona: diagnóstico y tratamiento
García-Cruz, E., & Alcaraz, A. (2020) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2019.10.009 · Cited by 10
Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events
Kharaba, Z. J., Buabeid, M. A., Ibrahim, N. A., Jirjees, F., Al-Obaidi, H. J., Kaddaha, A., Khajehkarimoddini, L., & Alfoteih, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110423 · Cited by 10
Aggarwal, V., Menon, A. S., & Verma, V. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_289_21 · Cited by 10
RetractedMorley, J. E. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.07.009 · Cited by 10
Lee, J., Shah, P. H., Uma, D., Salvi, D. J., Rabbani, R., & Hamid, P. (2021) · Cureus · doi:10.7759/cureus.17475 · Cited by 10
Zeng, B., Qiu, S., Xiong, X., Su, X., Zhang, Z., Wei, Q., & Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1009900 · Cited by 9
Rastrelli, G., Antonio, L., Carrier, S., Isidori, A. M., & Maggi, M. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf025 · Cited by 9
Glueck, C. J., Lee, K., Prince, M., Jetty, V., Shah, P. K., & Wang, P. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616661833 · Cited by 9
Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?
Cassimatis, D. C., Crim, M. T., & WENGER, N. K. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0496-0 · Cited by 9
Self-citationEvaluation and Treatment of Male Hypogonadism
Sargis, R. M., & Davis, A. M. (2018) · JAMA · doi:10.1001/jama.2018.3182 · Cited by 9
Chang, Y., & Wann, D. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.819644 · Cited by 8
Musculoskeletal Aging, Sarcopenia, and Cancer
Cesari, M., Calvani, R., & Marzetti, E. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_59 · Cited by 10
The Intersection of Medicine and Urology
Miner, M. M., Heidelbaugh, J. J., Paulos, M., Seftel, A. D., Jameson, J., & Kaplan, S. A. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.11.002 · Cited by 9
Risks of Serious Injury with Testosterone Treatment
Yarnell, C. J., Thiruchelvam, D., & Redelmeier, D. A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.07.037 · Cited by 10
Diagnosis and Evaluation of Hypogonadism
Matsumoto, A. M. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.001 · Cited by 9
Self-citationThe appropriateness and persistence of testosterone replacement therapy in Ontario
Martins, D., Yao, Z., Tadrous, M., Shah, B. R., Juurlink, D. N., Mamdani, M., & Gomes, T. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4083 · Cited by 9
Wallis, C. J. D., Saskin, R., Narod, S. A., Law, C., Kulkarni, G. S., Seth, A. K., & Nam, R. K. (2017) · British Journal of Urology · doi:10.1111/bju.13918 · Cited by 9
Coyoy-Salgado, A., Segura-Uribe, J. J., Salgado‐Ceballos, H., Castillo-Mendieta, T., Sánchez‐Torres, S., Freyermuth-Trujillo, X., Orozco-Barrios, C. E., Orozco-Suárez, S. A., Feria-Romero, I. A., Pinto‐Almazán, R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12071478 · Cited by 8
Connolly, M. J., Kerse, N. M., WILKINSON, T. J., Menzies, O. H., Rolleston, A. K., Chong, Y. H., Broad, J., Moyes, S. A., Jatrana, S., & Teh, R. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016572 · Cited by 8
Macdowall, W. G., Clifton, S., Palmer, M. J., Tanton, C., Copas, A. J., Lee, D. M., Mitchell, K. R., Mercer, C. H., Sonnenberg, P., Johnson, A. M., et al. (2021) · The Journal of Sex Research · doi:10.1080/00224499.2021.1968327 · Cited by 8
Liu, P., Wei, D., Nie, L., Fan, K., Xu, Q., Wang, L., Wang, J., Song, Y., Wang, M., Liu, X., et al. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106669 · Cited by 9
Self-citationThe anabolic applications of androgens in older adults with functional limitations
Gattu, A. K., Goldman, A. L., Guzelce, E. C., Galbiati, F., & Bhasin, S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09766-1 · Cited by 9
Self-citationLong vs Short Acting Testosterone Treatments: A Look at the Risks
Gurayah, A. A., Dullea, A. D., Weber, A., Masterson, J. M., Khodamoradi, K., Mohamed, A. I., & Ramasamy, R. (2022) · Urology · doi:10.1016/j.urology.2022.11.016 · Cited by 8
Jasuja, R., Pencina, K. M., Lawney, B. P., Stephens‐Shields, A. J., Ellenberg, S. S., Snyder, P. J., & Bhasin, S. (2024) · Andrology · doi:10.1111/andr.13707 · Cited by 8
Self-citationAndrogen Therapy and Rehospitalization in Older Men With Testosterone Deficiency
Baillargeon, J., Deer, R., Kuo, Y., Zhang, D., Goodwin, J. S., & Volpi, E. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.03.016 · Cited by 8
A Content Analysis of Testosterone Websites: Sex, Muscle, and Male Age-Related Thematic Differences
Ivanov, N., Vuong, J., & Gray, P. B. (2017) · American Journal of Men s Health · doi:10.1177/1557988317734667 · Cited by 8
Yu, J. C.-K., Buchman, S. R., Gosain, A. K., Havlik, R. J., Wang, T., Lam, P.-S., & Masoumy, M. (2021) · FACE · doi:10.1177/27325016211060232 · Cited by 8
Development of the Hypogonadism Impact of Symptoms Questionnaire Short Form: Qualitative Research
Gelhorn, H. L., Bodhani, A. R., Wahala, L. S., Sexton, C., Landrian, A. S., Miller, M. G., Derogatis, L. R., Dobs, A. S., & Revicki, D. A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.09.007 · Cited by 8
Traish, A. M., Vance, J. C., & Morgentaler, A. (2016) · EMBO Reports · doi:10.15252/embr.201643642 · Cited by 8
Rastrelli, G., & Forti, G. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_31-1 · Cited by 8
Glueck, C. J., Goldenberg, N., & Wang, P. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000637 · Cited by 9
Brinkley, T. E., Berger, M., Callahan, K. E., Fieo, R. A., Jennings, L. A., Morris, J. K., Wilkins, H., & Kritchevsky, S. B. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly041 · Cited by 8
Clavell-Hernández, J., & Wang, R. (2018) · The World Journal of Men s Health · doi:10.5534/wjmh.17050 · Cited by 8
Owens, S. J., Weickert, T. W., Purves-Tyson, T. D., Ji, E., White, C., Galletly, C. A., Liu, D., O׳Donnell, M., & Weickert, C. S. (2018) · Complex Psychiatry · doi:10.1159/000495062 · Cited by 8
Efficacy of Xianling Gubao capsule in treating sarco-osteopenia
Chen, Q., Zeng, J., Chen, Y., Yang, Y., Zhang, T., Luo, T., & Huang, H. (2019) · Medicine · doi:10.1097/md.0000000000015672 · Cited by 8
Testosterontherapie im Alter bei Hypogonadismus und Komorbiditäten
Zitzmann, M. (2020) · Der Internist · doi:10.1007/s00108-020-00796-y · Cited by 9
Use, Misuse, and Abuse of Androgens
Handelsman, D. J. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_44 · Cited by 8
Anaissie, J. E., Pastuszak, A. W., & Khera, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00012-3 · Cited by 8
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism
Bhasin, S., Burnett, A. L. “., Gagliano‐Jucá, T., Storer, T. W., Reid, K. F., Shang, Y. V., Privat, F., Chandra, M. S., Weiss, M., Beleva, Y. M., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.1343 · Cited by 7
Self-citationMedical Treatment of Hypogonadism in Men
Mani, S. B., & Clavijo, R. I. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2021.12.008 · Cited by 7
Wittert, G., Robledo, K. P., Handelsman, D. J., Inder, W. J., Stuckey, B. G. A., Yeap, B. B., Bracken, K., Allan, C. A., Jesudason, D. R., Jenkins, A. J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf060 · Cited by 8
The Rise and Fall of Estrogen Therapy: Is Testosterone for “Manopause” Next?
Costello, B. T., Sprung, K., & Coulter, S. (2017) · Texas Heart Institute Journal · doi:10.14503/thij-17-6360 · Cited by 7
DEFICIÊNCIA ANDROGÊNICA DO ENVELHECIMENTO MASCULINO E A REPOSIÇÃO DE TESTOSTERONA
Silva, K. R., & Linartevichi, V. F. (2021) · FAG JOURNAL OF HEALTH (FJH) · doi:10.35984/fjh.v3i1.306 · Cited by 7
Testosterone Therapy: Increase in Hematocrit is Associated with Decreased Mortality
Strange, R. C., König, C. S., Ahmed, A., Hackett, G. I., Haider, A., Haider, K. S., Desnerck, P., Saad, F., Lorde, N., Maarouf, A., et al. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0019 · Cited by 7
Morgentaler, A. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.07.075 · Cited by 7
Gan, E. H., & Quinton, R. (2016) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2016.307 · Cited by 7
Sex, Gender, and Transgender: Metabolic Impact of Cross Hormone Therapy
Santos, R. D. S., Frank, A. P., Nelson, M. D., Garcia, M. M., Palmer, B. F., & Clegg, D. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_27 · Cited by 8
Arora, S., Moclair, B., Murphy, K., Jaffe, J. S., & Kaminetsky, J. C. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.09.017 · Cited by 7
Mok, S. F., Fennell, C., Savkovic, S., Turner, L., Jayadev, V., Conway, A. J., & Handelsman, D. J. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz195 · Cited by 7
Rishi, S., Olurinde, O., Peter, W., Sharma, M., Garcia‐Touza, M., Archana, G., Savin, V. A., Barua, R. S., Ram, S., & Thomas, W. G. (2020) · Annals of Nephrology · doi:10.36959/832/400 · Cited by 6
Gleave, M. E., & Klotz, L. H. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.08.010 · Cited by 7
Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism)
Saad, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_23 · Cited by 6
Is Testosterone Replacement Safe in Men with Cardiovascular Disease?
Ahmed, T., Alattar, M., Pantalone, K. M., & Haque, R. U. (2020) · Cureus · doi:10.7759/cureus.7324 · Cited by 9
Conclusions about testosterone therapy and cardiovascular risk
Anawalt, B., & Yeap, B. B. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_7_18 · Cited by 7
Reproductive and Nonreproductive Actions of Testosterone
Bhasin, S., & Jasuja, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65412-0 · Cited by 7
Self-citationNanocarriers of Fertility: Mesenchymal Stem Cell‐Derived Exosomes in Male Reproductive Repair
Mahrooghi, D., Abdi, M., Soleimanzadeh, F., Abdi, S., Ojaroodi, A. F., & Karimzadeh, H. (2025) · Cell Biology International · doi:10.1002/cbin.70114 · Cited by 7
Becerra, C. A. G., Gallardo, M. I. A., Garcia, J. E. J., Soltero-Molinar, V., Parra-Camaño, L. F., Rivera-Rocha, M. I., Garcia-Becerra, N., & García-Gutiérrez, C. M. (2026) · International Journal of Impotence Research · doi:10.1038/s41443-026-01237-4 · Cited by 6
Reproductive endocrinology and aging in human males: An evolutionary perspective
Bribiescas, R. G. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105898 · Cited by 6
Pharmacological targeting of age-related changes in skeletal muscle tissue
Leuchtmann, A. B., & Handschin, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.030 · Cited by 7
Hypogonadismus und Infertilität des Mannes
Zitzmann, M. (2019) · Gynäkologische Endokrinologie · doi:10.1007/s10304-019-00277-y · Cited by 6
Panizzon, M. S., Bree, K. K., Hsieh, T., Hauger, R. L., Xian, H., Jacobson, K. C., Lyons, M. J., & Franz, C. E. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.08.016 · Cited by 6
Majumdar, S., Mukherjee, J. J., Ray, S., Goswami, S., Jude, E. B., Biswas, A. K., Hanumanthu, A., John, M., Sinha, B., Ghosal, S., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102191 · Cited by 8
Segerstrom, S. C., Reed, R. G., & Karr, J. E. (2022) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001086 · Cited by 6
Samuel, G. S., & Swee, D. S. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-307 · Cited by 6
Optimizing the Design of Clinical Trials to Evaluate the Efficacy of Function-Promoting Therapies
Bhasin, S., Cawthon, P. M., Correa‐de‐Araujo, R., Storer, T. W., Volpi, E., Newman, A. B., Dioh, W., Tourette, C., Evans, W. J., & Fielding, R. A. (2023) · The Journals of Gerontology Series A · doi:10.1093/gerona/glad024 · Cited by 6
Self-citationLi, Z., Zhu, C., Yin, C., Li, H., Liu, Y., & Li, J. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117817 · Cited by 6
Bulbocavernosus muscle area as a novel marker for hypogonadism
Gupta, N., Carvajal, M. M. T., Jurewicz, M., & Gilbert, B. R. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.11.002 · Cited by 6
What does the research say about androgen use and cerebrovascular events?
Sadaie, M. R., Farhoudi, M., Zamanlu, M., Aghamohammadzadeh, N., Amouzegar, A., Rosenbaum, R. E., & Thomas, G. A. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618773318 · Cited by 7
Schwarzman, L. S., de Souza, R. P., Ohlander, S. J., Mima, M., Abern, M. R., Andriole, G. L., Freedland, S. J., & Moreira, D. M. (2019) · Urology · doi:10.1016/j.urology.2019.11.004 · Cited by 6
Sansone, A., Kliesch, S., Dugas, M., Sandhowe‐Klaverkamp, R., Isidori, A. M., Schlatt, S., & Zitzmann, M. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01561-0 · Cited by 6
Sexual Dysfunction in Chronic Kidney Disease
Johansen, K. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00037-1 · Cited by 6
Haberlen, S., Jacobson, L. P., Palella, F., Dobs, A. S., Plankey, M. W., Lake, J., Kingsley, L., Stall, R. D., Post, W. S., & Brown, T. T. (2018) · HIV Medicine · doi:10.1111/hiv.12644 · Cited by 6
Testosterone Therapy for the Treatment of Age-Related Hypogonadism: Risks with Uncertain Benefits
Nguyen, C. P., Hirsch, M., Kaul, S., Woods, C. M., & Joffe, H. V. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0018 · Cited by 6
Testosterone Replacement Therapy
Kloner, R. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416646938 · Cited by 6
Testosterone Concentration and Incident Depression in Older Men: A Longitudinal Cohort Study
Forbes, M., Lotfaliany, M., Tran, C., Mohebbi, M., Woods, R. L., McNeil, J. J., & Berk, M. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf019 · Cited by 5
Impact of Symptoms of Late-Onset Hypogonadism as a Potential Driver of Presenteeism
Shirakawa, T., Ide, H., Ikehata, Y., Lü, Y., Kinouchi, R., Iwasa, T., Koga, K., Tateishi, S., Fujino, Y., Yasui, T., et al. (2025) · American Journal of Men s Health · doi:10.1177/15579883251343972 · Cited by 5
Chang, S., Pedersen, L. H., Skakkebaek, A. H., Berglund, A., & Gravholt, C. H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf619 · Cited by 5
Metabolic Messengers: testosterone
Mauvais‐Jarvis, F., & Bhasin, S. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01431-6 · Cited by 6
Self-citation
Metadata
- Authors
- Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., Gill, T. M., Barrett-Connor, E., Swerdloff, R. S., Wang, C., Ensrud, K. E., Lewis, C. E., Farrar, J. T., Cella, D., Rosen, R. C., Pahor, M., Crandall, J. P., Molitch, M. E., Cifelli, D., Dougar, D., Fluharty, L., Resnick, S. M., Storer, T. W., Anton, S., Basaria, S., Diem, S. J., Hou, X., Mohler, E. R., Parsons, J. K., Wenger, N. K., Zeldow, B., Landis, J. R., & Ellenberg, S. S.
- Affiliations
- University of Pennsylvania (US)
- Brigham and Women's Hospital (US)
- Baylor College of Medicine (US)
- University of Washington (US)
- From the Division of Endocrinology, Diabetes, and Metabolism (P.J.S.), the Department of Biostatistics and Epidemiology (A.J.S.-S., J.T.F., X.H., B.Z., J.R.L., S.S.E.), the Center for Clinical Epidemiology and Biostatistics (D. Cifelli, D.D., L.F.), and the Division of Cardiovascular Disease, Section of Vascular Medicine, Department of Medicine (E.R.M.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Research Program in Men’s Health: Aging and Metabolism, Brigham and Women’s...
- University of Pittsburgh (US)
- Yale University (US)
- University of California San Diego (US)
- The Lundquist Institute (US)
- University of Minnesota (US)
- Northwestern University (US)
- New England Research Institutes (US)
- University of Florida (US)
- Albert Einstein College of Medicine (US)
- National Institutes of Health (US)
- Emory University (US)
- ORCID
- Snyder, Peter J.
- Bhasin, Shalender
- Cunningham, Glenn R.
- Matsumoto, Alvin M.
- Cauley, Jane A.
- Gill, Thomas M.
- Barrett-Connor, Elizabeth
- Swerdloff, Ronald S.
- Wang, Christina
- Ensrud, Kristine E.
- Lewis, Cora E.
- Farrar, John T.
- Cella, David
- Crandall, Jill P.
- Molitch, Mark E.
- Resnick, Susan M.
- Storer, Thomas W.
- Anton, Stephen
- Basaria, Shehzad
- Diem, Susan J.
- Hou, Xiaoling
- Parsons, J. Kellogg
- Wenger, Nanette K.
- Zeldow, Bret
- Landis, J. Richard
- Ellenberg, Susan S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-02-18
- Volume
- 374
- Issue
- 7
- Pages
- 611-624
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5209754
- OpenAlex
- W2324158400
- Cited by
- 890
- References
- 40
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 73 · 2023: 97 · 2022: 79 · 2021: 65 · 2020: 81 · 2019: 76 · 2018: 103 · 2017: 106 · 2016: 86
- FWCI
- 124.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p60dk079626-05, UL1TR000142)
- National Institute on Aging (U01AG030644, P30-AG013679, R01AG037679, K24AG021507, K07AG043587, R01 AG37679, P30AG024827, P30AG028740, P30AG021342)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK079626, P60-DK-079626, P30DK079626)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Keywords
- testosterone replacement therapy, older men, hypogonadism, testosterone gel, sexual function, erectile function, sexual desire, physical function, walking distance, vitality, depressive symptoms, mood, adverse events
- MeSH terms
- Aged, Depression, Double-Blind Method, Fatigue, Humans, Libido, Male, Reference Values, Sexual Behavior, Testosterone, Walking, Prostate-Specific Antigen, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
